The comparison of pathogenic role and mechanism of Kallistatin and PEDF in tumors

IF 9.7 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-01-27 DOI:10.1016/j.bbcan.2025.189273
Jiayi Lyu , Simin Wang , Jingnan Chen , Xia Yang , Guoquan Gao , Ti Zhou
{"title":"The comparison of pathogenic role and mechanism of Kallistatin and PEDF in tumors","authors":"Jiayi Lyu ,&nbsp;Simin Wang ,&nbsp;Jingnan Chen ,&nbsp;Xia Yang ,&nbsp;Guoquan Gao ,&nbsp;Ti Zhou","doi":"10.1016/j.bbcan.2025.189273","DOIUrl":null,"url":null,"abstract":"<div><div>Tumors are diseases caused by abnormal cell division and growth, which can be life-threatening if not treated properly. Serpin inhibitors play a crucial role in regulating pathophysiological process and are promising drug targets. Kallistatin (SERPINA4) and Pigment Epithelium-Derived Factor (PEDF, SERPINF1) are two serpins that lack protease inhibitory activity but are abundant in blood. They exhibit anti-angiogenic effects and are involved in tumorigenesis. The pathogenic role and mechanism of Kallistatin and pigment epithelium-derived factor (PEDF) have been extensively studied for their potential use in cancer therapy. Kallistatin and PEDF play significant roles in controlling tumor growth and progression. While they share some common mechanisms of action, such as promoting apoptosis and inhibiting angiogenesis, they also have distinct differences in effectiveness and range of anti-tumor activities. This review compares and contrasts the expression patterns, structural features, expression regulation, disease roles, signaling pathways, and potential clinical value of Kallistatin and PEDF, aiming to provide a comprehensive understanding of their biomedical and clinical potential.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 2","pages":"Article 189273"},"PeriodicalIF":9.7000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Reviews on cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304419X25000150","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumors are diseases caused by abnormal cell division and growth, which can be life-threatening if not treated properly. Serpin inhibitors play a crucial role in regulating pathophysiological process and are promising drug targets. Kallistatin (SERPINA4) and Pigment Epithelium-Derived Factor (PEDF, SERPINF1) are two serpins that lack protease inhibitory activity but are abundant in blood. They exhibit anti-angiogenic effects and are involved in tumorigenesis. The pathogenic role and mechanism of Kallistatin and pigment epithelium-derived factor (PEDF) have been extensively studied for their potential use in cancer therapy. Kallistatin and PEDF play significant roles in controlling tumor growth and progression. While they share some common mechanisms of action, such as promoting apoptosis and inhibiting angiogenesis, they also have distinct differences in effectiveness and range of anti-tumor activities. This review compares and contrasts the expression patterns, structural features, expression regulation, disease roles, signaling pathways, and potential clinical value of Kallistatin and PEDF, aiming to provide a comprehensive understanding of their biomedical and clinical potential.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Biochimica et biophysica acta. Reviews on cancer
Biochimica et biophysica acta. Reviews on cancer 医学-生化与分子生物学
CiteScore
17.20
自引率
0.00%
发文量
138
审稿时长
33 days
期刊介绍: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer encompasses the entirety of cancer biology and biochemistry, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signaling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. It publishes mini-reviews and full reviews.
期刊最新文献
Alpha-1 antitrypsin deficiency and primary liver cancers Cancer-associated fungi: An emerging powerful player in cancer immunotherapy Potentially diagnostic and prognostic roles of piRNAs/PIWIs in pancreatic cancer: A review Challenges and opportunities in single-domain antibody-based tumor immunotherapy MOMP: A critical event in cell death regulation and anticancer treatment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1